Jennison Associates
JUNO

Jennison Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Jennison Associates’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,725,236
Closed -$78.9M – 722
2017
Q4 		$78.9M Sell
1,725,236
-263,472
-13% -$13.1M 0.08% 197
2017
Q3 		$89.2M Buy
1,988,708
+1,229,622
+162% +$41.9M 0.09% 178
2017
Q2 		$22.7M Buy
+759,086
New +$18.7M 0.02% 390

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Jennison Associates's JUNO Position: Q1 2018 in Review

Jennison Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,725,236 shares — an estimated $78.9M sold.

Jennison Associates first reported a position in JUNO in Q2 2017 and held it in 3 quarters. The position peaked at $89.2M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Jennison Associates reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Jennison Associates sold 1,725,236 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $78.9M.
  • Jennison Associates first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Jennison Associates's Juno Therapeutics, Inc. position peaked at $89.2M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Jennison Associates's 13F filing for Q1 2018, filed 20 Apr 2018.